Selectively Targeting Mcl-1 for the Treatment of Acute Myelogenous Leukemia and Solid Tumors

Overview

Journal Genes Dev

Specialty Molecular Biology

Date 2012 Feb 21

PMID 22345513

Citations 55

Authors

Gregory J Gores

Scott H Kaufmann

Affiliations

Soon will be listed here.

Abstract

Bcl-2, Bcl-x(L), Mcl-1, and A1 are the predominant anti-apoptotic members of the Bcl-2 family in somatic cells. Malignant B lymphocytes are critically dependent on Bcl-2 or Bcl-x(L) for survival. In contrast, a new study by Glaser and colleagues in the January 15, 2012, issue of Genes & Development (pp. 120-125) demonstrates that Mcl-1 is essential for development and survival of acute myelogenous leukemia cells. These results provide new impetus for the generation of selective Mcl-1 inhibitors.

Citing Articles

Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells.

Shah H, Hill T, Lim J, Fairlie D J Cell Commun Signal. 2023; 17(4):1293-1307.

PMID: 37991681 PMC: 10713943. DOI: 10.1007/s12079-023-00791-6.

Targeting MCL-1 protein to treat cancer: opportunities and challenges.

Tantawy S, Timofeeva N, Sarkar A, Gandhi V Front Oncol. 2023; 13:1226289.

PMID: 37601693 PMC: 10436212. DOI: 10.3389/fonc.2023.1226289.

Ubiquitin-proteasome pathway-mediated regulation of the Bcl-2 family: effects and therapeutic approaches.

Tang G, Lai J, Pervaiz S Haematologica. 2023; 109(1):33-43.

PMID: 37584295 PMC: 10772529. DOI: 10.3324/haematol.2023.283730.

Protein-protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies.

Lucero B, Francisco K, Liu L, Caffrey C, Ballatore C Trends Pharmacol Sci. 2023; 44(7):474-488.

PMID: 37263826 PMC: 11003449. DOI: 10.1016/j.tips.2023.04.007.

Radiation Response of Human Leukemia/Lymphoma Cells was Improved by 7-Geranyloxycoumarin.

Bagheri R, Rassouli F, Gholamhosseinian H, Ebrahimi K, Mahdavi S, Goudarzi S Dose Response. 2022; 20(3):15593258221124479.

PMID: 36158737 PMC: 9500271. DOI: 10.1177/15593258221124479.

References

Karp J, Smith B, Resar L, Greer J, Blackford A, Zhao M . Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011; 117(12):3302-10. PMC: 3069672. DOI: 10.1182/blood-2010-09-310862. View

Opferman J . Life and death during hematopoietic differentiation. Curr Opin Immunol. 2007; 19(5):497-502. DOI: 10.1016/j.coi.2007.06.002. View

Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk S, Farrugia D . Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004; 64(10):3517-24. DOI: 10.1158/0008-5472.CAN-03-2770. View

De Biasio A, Vrana J, Zhou P, Qian L, Bieszczad C, Braley K . N-terminal truncation of antiapoptotic MCL1, but not G2/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells. J Biol Chem. 2007; 282(33):23919-36. DOI: 10.1074/jbc.M700938200. View

Karp J, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella T . Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. 2005; 11(23):8403-12. DOI: 10.1158/1078-0432.CCR-05-1201. View

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

Dewson G, Kratina T, Sim H, Puthalakath H, Adams J, Colman P . To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol Cell. 2008; 30(3):369-80. DOI: 10.1016/j.molcel.2008.04.005. View

Walensky L . From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol. 2011; 30(5):554-7. PMC: 4879972. DOI: 10.1200/JCO.2011.37.9339. View

Gavathiotis E, Reyna D, Davis M, Bird G, Walensky L . BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell. 2010; 40(3):481-92. PMC: 3050027. DOI: 10.1016/j.molcel.2010.10.019. View

10.

Ding Q, He X, Hsu J, Xia W, Chen C, Li L . Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007; 27(11):4006-17. PMC: 1900029. DOI: 10.1128/MCB.00620-06. View

11.

Frohling S, Scholl C, Gilliland D, Levine R . Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005; 23(26):6285-95. DOI: 10.1200/JCO.2005.05.010. View

12.

Cheng E, Wei M, Weiler S, Flavell R, Mak T, LINDSTEN T . BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001; 8(3):705-11. DOI: 10.1016/s1097-2765(01)00320-3. View

13.

Kvinlaug B, Chan W, Bullinger L, Ramaswami M, Sears C, Foster D . Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res. 2011; 71(12):4117-29. PMC: 3119437. DOI: 10.1158/0008-5472.CAN-11-0176. View

14.

Mills J, Hippo Y, Robert F, Chen S, Malina A, Lin C . mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A. 2008; 105(31):10853-8. PMC: 2504845. DOI: 10.1073/pnas.0804821105. View

15.

Wertz I, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson D . Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011; 471(7336):110-4. DOI: 10.1038/nature09779. View

16.

Pratz K, Cho E, Levis M, Karp J, Gore S, McDevitt M . A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010; 24(8):1437-44. PMC: 2921005. DOI: 10.1038/leu.2010.132. View

17.

Ravandi F, Cortes J, Jones D, Faderl S, Garcia-Manero G, Konopleva M . Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28(11):1856-62. PMC: 2930809. DOI: 10.1200/JCO.2009.25.4888. View

18.

Kaufmann S, Karp J, Svingen P, Krajewski S, Burke P, Gore S . Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood. 1998; 91(3):991-1000. View

19.

Lee Y, Isham C, Kaufman S, Bible K . Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol Cancer Ther. 2006; 5(1):138-48. DOI: 10.1158/1535-7163.MCT-05-0235. View

20.

Placzek W, Wei J, Kitada S, Zhai D, Reed J, Pellecchia M . A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis. 2011; 1:e40. PMC: 3032312. DOI: 10.1038/cddis.2010.18. View